IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i4d10.1007_s40264-020-01032-0.html
   My bibliography  Save this article

The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to

Author

Listed:
  • Avy Violari

    (Chris Hani Baragwanath Hospital, University of the Witwatersrand)

  • Maysseb Masenya

    (Shandukani Research Centre, Wits RHI)

  • Stephane Blanche

    (Hôpital Necker–Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP) and Faculté de Médecine Paris Descartes)

  • Simon Vanveggel

    (Janssen Pharmaceutica NV)

  • Veerle Hufkens

    (Janssen Pharmaceutica NV)

  • Polan Chetty

    (Janssen Research and Development)

  • Magda Opsomer

    (Janssen Pharmaceutica NV)

Abstract

Introduction Darunavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor boosted with ritonavir (DRV/r) or cobicistat. Objective This study provided continued access to DRV/r and assessed long-term safety in patients aged 3 to

Suggested Citation

  • Avy Violari & Maysseb Masenya & Stephane Blanche & Simon Vanveggel & Veerle Hufkens & Polan Chetty & Magda Opsomer, 2021. "The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to," Drug Safety, Springer, vol. 44(4), pages 439-446, April.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:4:d:10.1007_s40264-020-01032-0
    DOI: 10.1007/s40264-020-01032-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-020-01032-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-020-01032-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:4:d:10.1007_s40264-020-01032-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.